Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (£272m) over five years because of the United States' insistence on confidential biological samples.
This move was revealed after a government memo dated December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
An official representative later explained that the US was demanding access to biological samples for scientific study and profit while was not willing to share the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has urged further negotiations to reach a agreement agreeable to all parties so the nation's vital HIV treatment initiative can proceed.
Wider Background
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a high court halted a related deal with the US after concerns were raised about the safety of citizens' medical information.
Since returning to the presidency recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
USAID had administered assistance for the US government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government agreements to boost transparency and responsibility.
According to reports, Sixteen African countries have so far signed these new health pacts, representing over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation might have yielded extraordinary advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information over an extended period, with no equivalent promise of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," he stated.
"Effectively, our country would provide the basic resources for medical research without any assurance that the resulting innovations would be available to our population should a new pandemic arise."
National Interest and International Frameworks
Mangwana further said that the American exit from the World Health Organization (WHO) and its push of one-on-one health agreements were disrupting frameworks previously set up via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to deal with future global health emergencies.
"This mechanism is intended to ensure that when a country provides its information, the benefits – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to develop them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to further dialogue with our US partners on how subsequent collaboration could be structured in a manner that honours the independence and interests of both nations."
Health Experts Reaction
A leading public health body expressed it understood the government's concerns, but urged that negotiations should continue given that a large portion of the nation's Aids initiatives depended on foreign aid.
"If technical issues exist, including those relating to information security or agreement terms, these can often be addressed via technical clarification and negotiated safeguards," the group commented.
The situation emphasises the ongoing challenges between receiving crucial foreign assistance and safeguarding local interests in an ever more data-driven world.